Threshold Pharmaceuticals News
Threshold Pharmaceuticals: A Biotech That Investors Need To Know About
Celgene Soars in 2013; What Does the Future Hold?
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual MeetingMarketwired Jun 2
Threshold Pharmaceuticals, Inc. today announced data from two ongoing Phase 1/2 trials evaluating TH-302, an investigational hypoxia-targeted drug, at the 49th Annual Meeting of the American Society of ...
Investors eyeing a purchase of Threshold Pharmaceuticals Inc stock, but cautious about paying the going market price of $5.51/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $2.50 strike, which has a bid at the time of this writing of 40 cents.
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersMay 20
Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor ConferencesMarketwired May 9
Threshold Pharmaceuticals, Inc. today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences:
Threshold Pharmaceuticals, Inc. , today reported financial results for the first quarter 2013. Revenue for the first quarter ended March 31, 2013 was $2.9 million. The operating loss for the first quarter ...